Velan Calls for Increased Transparency at Progenics Pharmaceuticals During Q1 Earnings Call

Thursday, May 9, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

Filed Preliminary Proxy Materials Seeking Stockholder Support Against the Election of Peter J. Crowley and Michael D. Kishbauch at the Company's 2019 Annual Meeting to Send a Clear Message that Meaningful Change is Required

11.

What is the cost of, and capacity covered by, the manufacturing arrangement with International Isotopes? Why have you not publicly disclosed this arrangement?

12.

How much will the MIP-1095 Phase 2 trial and AZEDRA basket trial cost?

13.

Why has the Company neither refinanced the Relistor non-recourse debt nor borrowed further against this valuable royalty stream to provide accretion (vs. management's seeming preference for dilutive equity issuances)? 



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store